Patient characteristics, N = 112
| Parameter . | Median [range] or no. (%) . |
|---|---|
| Age, y | 51 [17-96] |
| Follow-up, mo | 64 [2-70] |
| Therapy before imatinib | |
| Interferon alpha | 69 (62) |
| None | 43 (38) |
| Stage at start of imatinib therapy | |
| CP | 88 (79) |
| AP | 18 (16) |
| BP | 6 (5) |
| Best response to imatinib | |
| CHR | 58 (52) |
| MCyR | 41 (37) |
| CCyR | 29 (26) |
| Duration of response, mo | 24 [2-68] |
| Time on imatinib, mo | 32 [2-70] |
| Mutation at imatinib failure | 61 (54) |
| Imatinib failure | |
| Resistance | 107 (96) |
| Primary resistance | 2 (2) |
| Secondary resistance | 105 (94) |
| Cytogenetic resistance | 29 (26) |
| Hematologic resistance | 76 (68) |
| Intolerance | 5 (4) |
| Follow-up after 2nd TKI, mo | 17 [4-31] |
| Stage at 2nd TKI | |
| CP | 38 (34) |
| AP | 54 (48) |
| BP | 20 (18) |
| 2nd TKI | |
| Dasatinib | 56 (50) |
| Nilotinib | 54 (48) |
| Bosutinib | 2 (2) |
| Stage at 3rd TKI | |
| CP | 5 (28) |
| AP | 9 (50) |
| BP | 4 (22) |
| 3rd TKI | |
| Dasatinib | 15 (83) |
| Nilotinib | 3 (17) |
| Parameter . | Median [range] or no. (%) . |
|---|---|
| Age, y | 51 [17-96] |
| Follow-up, mo | 64 [2-70] |
| Therapy before imatinib | |
| Interferon alpha | 69 (62) |
| None | 43 (38) |
| Stage at start of imatinib therapy | |
| CP | 88 (79) |
| AP | 18 (16) |
| BP | 6 (5) |
| Best response to imatinib | |
| CHR | 58 (52) |
| MCyR | 41 (37) |
| CCyR | 29 (26) |
| Duration of response, mo | 24 [2-68] |
| Time on imatinib, mo | 32 [2-70] |
| Mutation at imatinib failure | 61 (54) |
| Imatinib failure | |
| Resistance | 107 (96) |
| Primary resistance | 2 (2) |
| Secondary resistance | 105 (94) |
| Cytogenetic resistance | 29 (26) |
| Hematologic resistance | 76 (68) |
| Intolerance | 5 (4) |
| Follow-up after 2nd TKI, mo | 17 [4-31] |
| Stage at 2nd TKI | |
| CP | 38 (34) |
| AP | 54 (48) |
| BP | 20 (18) |
| 2nd TKI | |
| Dasatinib | 56 (50) |
| Nilotinib | 54 (48) |
| Bosutinib | 2 (2) |
| Stage at 3rd TKI | |
| CP | 5 (28) |
| AP | 9 (50) |
| BP | 4 (22) |
| 3rd TKI | |
| Dasatinib | 15 (83) |
| Nilotinib | 3 (17) |
CP indicates chronic phase; AP, accelerated phase; BP, blastic phase; CHR, complete hematologic response; MCyR, major cytogenetic response; and CCyR, complete cytogenetic response.